# A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

> **NCT05358886** · PHASE3 · COMPLETED · sponsor: **Tetra Discovery Partners** · enrollment: 171 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** BPN14770/ zatolmilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05358886
- **Lead sponsor:** Tetra Discovery Partners
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-01
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-07-18
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358886, "A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05358886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*